NASDAQ:SERA Sera Prognostics (SERA) Stock Forecast, Price & News $3.25 +0.03 (+0.93%) (As of 09:30 AM ET) Add Compare Share Share Today's Range$3.25▼$3.2550-Day Range$3.20▼$3.9052-Week Range$1.10▼$4.25Volume313 shsAverage Volume813,035 shsMarket Capitalization$100.91 millionP/E RatioN/ADividend YieldN/APrice Target$6.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Sera Prognostics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside92.3% Upside$6.25 Price TargetShort InterestHealthy1.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.38) to ($1.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector973rd out of 980 stocksMedical Laboratories Industry22nd out of 22 stocks 3.3 Analyst's Opinion Consensus RatingSera Prognostics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.25, Sera Prognostics has a forecasted upside of 92.3% from its current price of $3.25.Amount of Analyst CoverageSera Prognostics has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.07% of the float of Sera Prognostics has been sold short.Short Interest Ratio / Days to CoverSera Prognostics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sera Prognostics has recently decreased by 2.46%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSera Prognostics does not currently pay a dividend.Dividend GrowthSera Prognostics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SERA. Previous Next N/A News and Social Media Coverage Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sera Prognostics insiders have not sold or bought any company stock.Percentage Held by Insiders15.60% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.32% of the stock of Sera Prognostics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sera Prognostics are expected to grow in the coming year, from ($1.38) to ($1.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sera Prognostics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sera Prognostics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSera Prognostics has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sera Prognostics (NASDAQ:SERA) StockSera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Read More Receive SERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter. Email Address SERA Stock News HeadlinesMay 25, 2023 | marketwatch.comSera Prognostics Reduces Headcount to Cut Costs in Optimization StrategyMay 25, 2023 | finance.yahoo.comSera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and RevenueJune 5, 2023 | Edge On The Street (Ad)AI is Unstoppable. Now Is The Time!AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.May 17, 2023 | americanbankingnews.comEquities Analysts Offer Predictions for Sera Prognostics, Inc.'s Q2 2023 Earnings (NASDAQ:SERA)May 15, 2023 | msn.comSera Prognostics CEO Critchfield to step down in JuneMay 15, 2023 | finance.yahoo.comSera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEOMay 11, 2023 | finanznachrichten.deSera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2023 Financial ResultsMay 10, 2023 | msn.comRecap: Sera Prognostics Q1 EarningsJune 5, 2023 | Edge On The Street (Ad)AI is Unstoppable. Now Is The Time!AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.May 10, 2023 | finance.yahoo.comSERA PROGNOSTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTSMay 10, 2023 | finance.yahoo.comSera Prognostics, Inc. (SERA) Reports Q1 LossMay 10, 2023 | marketwatch.comPremature Rupture of Membranes (PROM) Testing Market Report | Research Across The World 2031May 3, 2023 | benzinga.comSera Prognostics Stock (NASDAQ:SERA), DividendsApril 27, 2023 | finance.yahoo.comSera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2023 Financial Results on May 10, 2023April 27, 2023 | americanbankingnews.comSera Prognostics, Inc. (NASDAQ:SERA) Short Interest Down 24.9% in AprilApril 24, 2023 | finance.yahoo.comSera Prognostics, Inc. (SERA) Loses -13.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMarch 29, 2023 | americanbankingnews.comSera Prognostics, Inc. (NASDAQ:SERA) Expected to Earn Q1 2023 Earnings of ($0.37) Per ShareMarch 28, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Sera Prognostics, Inc. Raised by Analyst (NASDAQ:SERA)March 27, 2023 | finance.yahoo.comAll You Need to Know About Sera Prognostics, Inc. (SERA) Rating Upgrade to BuyMarch 27, 2023 | marketwatch.comLatest Premature Rupture of Membranes (PROM) Testing Market Growth Outlook 2023-2030 | New Report HighlightsMarch 27, 2023 | insidermonkey.comSera Prognostics, Inc. (NASDAQ:SERA) Q4 2022 Earnings Call TranscriptMarch 24, 2023 | finance.yahoo.comSera Prognostics Full Year 2022 Earnings: Revenues Miss ExpectationsMarch 24, 2023 | americanbankingnews.comQ1 2024 Earnings Forecast for Sera Prognostics, Inc. Issued By William Blair (NASDAQ:SERA)March 22, 2023 | finance.yahoo.comSera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue EstimatesMarch 22, 2023 | finance.yahoo.comSERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTSMarch 21, 2023 | markets.businessinsider.comSera Prognostics A earnings preview: what Wall Street is expectingMarch 21, 2023 | americanbankingnews.comSera Prognostics (SERA) to Release Quarterly Earnings on WednesdaySee More Headlines SERA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SERA Company Calendar Last Earnings3/22/2023Today6/05/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SERA CUSIPN/A CIK1534969 Webwww.seraprognostics.com Phone801-990-0520FaxN/AEmployees113Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.25 High Stock Price Forecast$11.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+92.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,190,000.00 Net Margins-12,891.82% Pretax Margin-12,891.82% Return on Equity-41.18% Return on Assets-36.71% Debt Debt-to-Equity Ratio0.01 Current Ratio5.23 Quick Ratio5.23 Sales & Book Value Annual Sales$270,000.00 Price / Sales373.75 Cash FlowN/A Price / Cash FlowN/A Book Value$2.91 per share Price / Book1.12Miscellaneous Outstanding Shares31,050,000Free Float26,208,000Market Cap$100.91 million OptionableNot Optionable Beta0.26 Key ExecutivesDr. Gregory C. Critchfield M.D. (Age 70)M.S., Exec. Chairman, CEO & Pres Comp: $775.1kMr. Robert G. Harrison (Age 57)Chief Information Officer Comp: $384.18kMr. Benjamin G. Jackson J.D. (Age 43)Gen. Counsel Comp: $410.75kDr. Steven W. GravesCo-Founder and Co-Chairman of The Scientific Advisory BoardDr. M. Sean Esplin M.D.Co-Founder and Co-Chairman of Scientific Advisory BoardMr. Jay M. Moyes M.B.A. (Age 69)MBA, Chief Financial Officer Dr. John J. Boniface Ph.D. (Age 60)Chief Scientific Officer Ms. Nadia F. Altomare (Age 52)Chief Commercial Officer Dr. Paul Kearney Ph.D. (Age 55)Chief Data Officer Dr. Michael R. Foley M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsBiodesixNASDAQ:BDSXEnzo BiochemNYSE:ENZMedTech AcquisitionNASDAQ:MTACPersonalisNASDAQ:PSNLGenetronNASDAQ:GTHView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCBought 21,919 shares on 5/16/2023Ownership: 0.469%State Street CorpBought 50,192 shares on 5/16/2023Ownership: 0.162%Jane Street Group LLCBought 30,507 shares on 5/16/2023Ownership: 0.098%Squarepoint Ops LLCBought 17,064 shares on 5/16/2023Ownership: 0.055%Susquehanna International Group LLPBought 10,136 shares on 5/16/2023Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions SERA Stock - Frequently Asked Questions Should I buy or sell Sera Prognostics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sera Prognostics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SERA shares. View SERA analyst ratings or view top-rated stocks. What is Sera Prognostics' stock price forecast for 2023? 3 Wall Street analysts have issued twelve-month price objectives for Sera Prognostics' stock. Their SERA share price forecasts range from $1.50 to $11.00. On average, they predict the company's stock price to reach $6.25 in the next year. This suggests a possible upside of 92.3% from the stock's current price. View analysts price targets for SERA or view top-rated stocks among Wall Street analysts. How have SERA shares performed in 2023? Sera Prognostics' stock was trading at $1.26 at the beginning of the year. Since then, SERA shares have increased by 157.9% and is now trading at $3.25. View the best growth stocks for 2023 here. When is Sera Prognostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our SERA earnings forecast. How were Sera Prognostics' earnings last quarter? Sera Prognostics, Inc. (NASDAQ:SERA) announced its earnings results on Wednesday, March, 22nd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.11. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.13 million. Sera Prognostics had a negative trailing twelve-month return on equity of 41.18% and a negative net margin of 12,891.82%. When did Sera Prognostics IPO? (SERA) raised $75 million in an initial public offering on Thursday, July 15th 2021. The company issued 4,687,500 shares at $15.00-$17.00 per share. What is Sera Prognostics' stock symbol? Sera Prognostics trades on the NASDAQ under the ticker symbol "SERA." Who are Sera Prognostics' major shareholders? Sera Prognostics' stock is owned by many different retail and institutional investors. Top institutional investors include Baker BROS. Advisors LP (5.77%), Sanders Morris Harris LLC (1.41%), Geode Capital Management LLC (0.47%), Riverview Capital Advisers LLC (0.33%), Requisite Capital Management LLC (0.18%) and State Street Corp (0.16%). Insiders that own company stock include Benjamin Jackson and John J Boniface. View institutional ownership trends. How do I buy shares of Sera Prognostics? Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sera Prognostics' stock price today? One share of SERA stock can currently be purchased for approximately $3.25. How much money does Sera Prognostics make? Sera Prognostics (NASDAQ:SERA) has a market capitalization of $100.91 million and generates $270,000.00 in revenue each year. The company earns $-44,190,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. How many employees does Sera Prognostics have? The company employs 113 workers across the globe. How can I contact Sera Prognostics? The official website for the company is www.seraprognostics.com. The company can be reached via phone at 801-990-0520 or via email at peter@capcommpartners.com. This page (NASDAQ:SERA) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sera Prognostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.